China Merchants Bank International (CMBI) argues in a recent sector note that global innovative-drug R&D demand has passed a substantive upward inflection, citing PharmCube data showing Q2 2026 global biotech private financing of USD 16.08 billion, up 103% year-on-year, and H1 2026 total innovative-drug financing of USD 26.75 billion across 505 deals, up 58.5%.

The rebound occurred without further US Federal Reserve rate cuts (fed funds held at 3.63% since December 2025), suggesting risk appetite rather than monetary easing is the driver. China contributed USD 5.81 billion (21.7% of global) with 79.1% growth, fuelled by record license-out momentum – H1 2026 China outbound deals reached 100 transactions worth over USD 99.7 billion, already exceeding full-year 2024 totals.

The financing recovery is transmitting directly into contract research and manufacturing orders. Charles River's discovery and safety assessment book-to-bill hit 1.19x with Q2 new orders up 38.5% to USD 700 million; IQVIA clinical CRO new orders rose 19.4% (book-to-bill 1.22x); Medpace new orders jumped 28.2% to a record; Samsung Biologics signed USD 2.9 billion in Q2 CDMO awards.

AI anxiety that depressed preclinical CRO stocks in February 2026 has faded, with management commentary from Charles River, IQVIA, and Lonza converging on the view that AI-generated candidates increase, rather than replace, the need for animal safety studies and clinical execution. CMBI notes large-pharma R&D spend among ten majors rose 40.6% to USD 80.3 billion in H1 2026, offsetting biotech caution, while geographic reshoring of capacity (GSK's Maryland plant, Lonza Visp expansion) will convert to CXO revenue only from 2027 to 2028, leaving near-term growth anchored in discovery and Phase I to II demand.